Disease · EFO_0009870
bone metastasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bone metastasis. Diseases, record EFO_0009870. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009870
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- bone metastasis
- Open Targets ID
- EFO_0009870
- Other names
- metastasis to bone
- Highest stage of its drugs
- Approval, for 3 of its 25 drugs, from DailyMed
Source Open Targets
Drugs25
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ZOLEDRONIC ACID | CHEMBL4303669 | Small molecule | Approval | DailyMed | 6 | 5 | 5 | Drugs and targets |
| RADIUM RA 223 DICHLORIDE | CHEMBL2107816 | Small molecule | Approval | DailyMed | 5 | 4 | 4 | Drugs and targets |
| DENOSUMAB | CHEMBL1237023 | Antibody | Approval | DailyMed | 4 | 3 | 3 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TANEZUMAB | CHEMBL2108567 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TISLELIZUMAB | CHEMBL4297840 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ENZALUTAMIDE | CHEMBL1082407 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 25
See all 25 drugsTargets50
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CYP19A1 | Aromatase | 3 | Cytochrome P450 19A1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha antagonist; Estrogen receptor alpha modulator; Estrogen receptor degrader | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| FDPS | Farnesyl pyrophosphate synthase | 2 | Farnesyl diphosphate synthase inhibitor | Approval | https://conductscience.org/library/genes/2224 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| TUBA1A | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 50
See all 50 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy | Phase 3 | 595 | 2024-04-25 | Lung Cancer Non-small Cell Stage IV | DENOSUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02609828 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy | Phase 3 | 156 | 2023-01-20 | Bone Metastasis, Cancer Pain | TANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02097303 | Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis | Phase 2 | 36 | 2018-02-01 | Prostate Cancer | ABIRATERONE ACETATE, RADIUM RA 223 DICHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03691493 | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | Phase 2 | 36 | 2025-02-17 | Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8 | ANASTROZOLE, EXEMESTANE, FULVESTRANT, LETROZOLE, PALBOCICLIB, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT02384382 | A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | Phase 2 | 23 | 2020-05-05 | Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer | ENZALUTAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | Phase 2 | 11 | 2013-03-18 | Kidney Cancer, Renal Cell Carcinoma | ATORVASTATIN, ZOLEDRONIC ACID ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT01119118 | ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer | Phase 2 | 6 | 2013-04-29 | Prostate Cancer | ZIBOTENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT02443103 | Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis | Not applicable | 4 | 2018-02-13 | Bone Cancer, Metastasis | GUANABENZ ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT04587427 | A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before | 1,067 | Bone Metastatic Castration-resistant Prostate Cancer | RADIUM RA-223 | Its record names the disease | ClinicalTrials.gov | ||
| NCT00334139 | Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer | Phase 4 | 411 | Prostate Cancer, Breast Cancer, Bone Metastasis | ZOLEDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| None, Standard Chemotherapy Only vs Standard Chemotherapy + Denosumab: deaths from any cause | 178 of 255 | 177 of 259 | 514 | NCT02129699 | Trial comparisons |
| None, Standard Chemotherapy Only vs Standard Chemotherapy + Denosumab: serious adverse events | 97 of 255 | 138 of 259 | 514 | NCT02129699 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009870
GET https://conductscience.org/api/diseases/v1/EFO_0009870/drugs?page=2